Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM: Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
NCT04775550Phase 2Active, not recruiting
- Start
- Mar 2021
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, bortezomib, lenalidomide and dexamethasone in smoldering multiple myeloma (SMM). Primary endpoint: Minimal Residual Disease Negative Rate at 2 years. Started Mar 2021; status: active, not recruiting.
02
Drugs
daratumumabbortezomiblenalidomidedexamethasone
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT04775550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04775550.